Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Heart Disease Health Center

Font Size

New Heart Stent Looks Good in Study

Xience V Experimental Drug-Coated Stent May Offer Advantages Over Current Devices

Stent May Promote Faster Healing continued...

And the metal tube itself is a highly malleable, cobalt-chromium blend. That makes it easier for the doctor to get it exactly where he wants it, Stone says.

The question, he tells WebMD, was whether the polymer and stent would work together.

To find out, the researchers studied 1,002 people with blockages in up to two arteries. About two-thirds got the Xience stent; the rest were implanted with the standard Taxus stent.

After implantation, participants were treated with the drug Plavix to prevent blood clots for at least six months.

After nine months, 8.1% of people who got the Taxus stent died, had a heart attack, or had artery reclogging, compared with only 4.6% of those who got the Xience stent.

The Xience stent also reduced reclogging of the treated arteries compared with the standard drug-coated stent (4.7% vs. 8.9%), Stone says.

The findings should satisfy regulatory hurdles set by the FDA for approving the device, Stone says.

In addition to Taxus, the Cypher drug-eluting stent, from Cordis Corp., a subsidiary of Johnson & Johnson, is also approved in the U.S.

Abbott, which makes Xience, funded the research. The company is expected to submit the data to the FDA by the end of the year.

Spencer B. King III, MD, head of interventional cardiology at Piedmont Hospital in Atlanta, says that if approved, Xience will offer another option for treating the more than 1 million Americans who undergo angioplasty each year.

That said, it won’t make the Taxus or Cypher stents obsolete, he says.

“All three stents are highly effective,” he tells WebMD. “It’s always good to have options.”

1 | 2

Today on WebMD

x-ray of human heart
A visual guide.
atrial fibrillation
Symptoms and causes.
heart rate graph
10 things to never do.
heart rate
Get the facts.
empty football helmet
red wine
eating blueberries
Simple Steps to Lower Cholesterol
Inside A Heart Attack
Omega 3 Sources
Salt Shockers
lowering blood pressure